Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.

@article{Blanke2011ImpactOY,
  title={Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.},
  author={Charles David Blanke and Brian M. Bot and David Thomas and Archie Bleyer and C H Kohne and Matthew T. Seymour and Aimery de Gramont and Richard M. Goldberg and Daniel J. Sargent},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 20},
  pages={2781-6}
}
PURPOSE Colorectal cancer predominantly occurs in the elderly, but approximately 5% of patients are 50 years old or younger. We sought to determine whether young age is prognostic, or whether it influences efficacy/toxicity of chemotherapy, in patients with advanced disease. METHODS We analyzed individual data on 6,284 patients from nine phase III trials of advanced colorectal cancer (aCRC) that used fluorouracil-based single-agent and combination chemotherapy. End points included progression… CONTINUE READING